You have accessRestricted access
Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial
Laurène Mansy, Agnès Caille, Martine Reynaud-Gaubert, Julien Bermudez, Philippe Bonniaud, Raphael Borie, Pierre-Yves Brillet, Jacques Cadranel, Isabelle Court-Fortune, Bruno Crestani, Marie-Pierre Debray, Mathilde Duprez, Anne Guillaumot, Sandrine Hirschi-Santelmo, Dominique Israel-Biet, Stéphane Jouneau, Karine Juvin, Mallorie Kerjouan, Julie Mankikian, Charles-Hugo Marquette, Jean-Marc Naccache, Hilario Nunes, Laurent Plantier, Grégoire Prevot, Sébastien Quetant, Julie Traclet, Victor Valentin, Yurdagul Uzunhan, Lidwine Wémeau-Stervinou, Vincent Cottin, Sylvain Marchand-Adam on behalf of the EVER-ILD investigators and the OrphaLung network
European Respiratory Journal 64 (3) 2401368; DOI: 10.1183/13993003.01368-2024 Published 12 September 2024